Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04076527
Other study ID # 2.0
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 19, 2019
Est. completion date March 2024

Study information

Verified date June 2023
Source University of Leipzig
Contact Thomas Berg, Prof.Dr.
Phone +49 341 97 12 330
Email thomas.berg@medizin.uni-leipzig.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The German PBC Cohort is a multi-centric, observational (non-interventional) study with three parallel groups. The main objective of this observational study is to describe the course of Primary biliary cholangitis (PBC) in patients in Germany under routine treatment with approved drugs. Therefore, the effectiveness and safety/tolerability of PBC treatment options in a real-life setting will be evaluated.


Description:

Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease. The course of the disease is characterized by a slow destruction of bile ducts, and progressive cholestasis. Prognosis depends on the development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) has been established as standard therapy for PBC and improves patients' long-term outcome. However, UDCA is not a uniformly effective drug, and the prognosis of PBC patients insufficiently responding to treatment is markedly worse. For patients with suboptimal treatment response to UDCA obeticholic acid (OCA) as newly approved medication (OCALIVA®) is available as second line treatment. Due to the low prevalence and the slowly progressive course of the disease it is very difficult to investigate the prognosis of subgroups of PBC patients or to evaluate the effectivness of therapeutic interventions on clinical outcomes. Therefore, several national or international registries (UK-PBC Consortium or the Global PBC Study Group) were founded to better characterize the clinical course of PBC patients. Since in Germany a registry for PBC does not exist, the German PBC Cohort is being implemented as observational study to collect data on treatment progress and success in clinical routine that reflects real world conditions in Germany as closely as possible. The effectiveness and safety/tolerability of PBC treatment options (UDCA as standard therapy and second-line treatment options like OCALIVA in case of inadequate UDCA treatment response) will be evaluated. In approximatly 40 sites in Germany routine data is collected. There are no specifications for the diagnosis, therapy and monitoring of the PBC patients. The documentation of the routine data is carried out alongside with guideline recommended treatment intervals of the patients. Furthermore, a critical criterion for the German PBC Cohort study is the involvement of a sufficient number of gastroenterology specialized practices and outpatient clinics that have consciously not been selected based on the strict specifications of a clinical trial and which provide routine treatment for PBC patients. In addition, patient access is designed to be open. Data will be collected on patient groups that represent a majority of the PBC patients in Germany, but who are not being investigated in clinical trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Diagnosis of PBC PBC diagnosis (consistent with AASLD and EASL practice guidelines), as demonstrated by the presence of at least two of the following three diagnostic factors: - History of elevated ALP levels for 6 months. - Positive anti-mitochondrial antibody (AMA) titer or if AMA negative or in low titer (<1:80) => PBC-specific antibodies: - anti-GP210 and/or - anti-SP100 and/or - antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex (OADC-E2), branched-chain-2-oxo-acid-dehydrogenase complex, (BCOADC-E2)]. - Liver biopsy consistent with PBC. 3. Medication-based treatment with at least one drug approved in Germany for the treatment of PBC 4. Availability of all following essential parameters at the initial diagnosis of PBC prior to the initiation of treatment with UDCA, 12 months after initiation of UDCA and if applicable at time point of secondary incomplete response: - Platelet count - Alkaline Phosphatase (ALP) - Total Bilirubin - Aspartate aminotransferase (AST/GOT) - Age at initial diagnosis of PBC 5. Patients must meet criteria of one of the cohorts (group 1/2/3) within this NIS according to design 6. written statement of informed consent Exclusion Criteria: Current participation in a phase I to IV interventional clinical trial for PBC or participation in another PBC registry.

Study Design


Intervention

Drug:
UDCA
Routine data is collected for UDCA therapy.
Ocaliva
Routine data is collected for OCA therapy.

Locations

Country Name City State
Germany University Hospital Aachen Aachen
Germany Charité - Campus Benjamin Franklin Berlin
Germany Charité-Campus Virchow-Klinikum Berlin
Germany Internal Practice Berlin
Germany Liver Center Checkpoint Berlin
Germany MVZ Gastroenterology Berlin
Germany Hospital Chemnitz Chemnitz
Germany University Hospital Cologne Cologne
Germany Internal Practice Dornstadt
Germany MVZ Düsseldorf Düsseldorf
Germany University hospital Düsseldorf Düsseldorf
Germany University Hospital Erlangen Erlangen
Germany St. Josef- Hospital Kupferdreh Essen
Germany University Hospital Essen Essen
Germany Internal Practice Frankfurt
Germany University Hospital J.W. Goethe- Universität Frankfurt am Main
Germany University Hospital Freiburg Freiburg
Germany University Hospital Gießen Gießen
Germany Gastroenerological-Oncological Practice Halle
Germany University Hospital Halle Halle
Germany Liver Center Hamburg - Asklepios Clinic St. Georg Hamburg
Germany Internal Practice Hameln
Germany MHH Hannover
Germany University Hospital Heidelberg Heidelberg
Germany Gastroenerological Practice Herne
Germany University hospital Saarland Homburg
Germany University Hospital Jena Jena
Germany Gastroenerological Practice Kassel
Germany Center for Gastroenterology and Hepatology Kiel Kiel
Germany University Hospital Schleswig-Holstein Campus Kiel Kiel
Germany Eugastro - Gastroenerological Practice Leipzig
Germany University Hospital Leipzig Leipzig
Germany MVZ Leverkusen Leverkusen
Germany University hospital Schleswig-Holstein Lübeck
Germany Internal Practice Hepatology Magdeburg
Germany University hospital Magdeburg Magdeburg
Germany University Hospital Mainz Mainz
Germany University Hospital Mannheim Mannheim
Germany Hospital LMU Munich
Germany Liver Center Munich Munich
Germany Technical University - Klinikum rechts der Isar Munich
Germany University Hospital Münster Münster
Germany Hospital Nuremberg Nuremberg
Germany Internal Practice Potsdam
Germany University Hospital Regensburg Regensburg
Germany Diakonie-Klinikum Schwäbisch Hall Schwäbisch Hall
Germany Internal Practice Schwerin
Germany University Hospital Tübingen Tübingen
Germany University Hospital Ulm Ulm
Germany St. Josefs-Hospital Wiesbaden

Sponsors (10)

Lead Sponsor Collaborator
University of Leipzig Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Hannover Medical School, Institute for Interdisciplinary Medicine, Hamburg, Intercept Pharma Europe Limited (IPEL), Leberhilfe Projekt gUG, Cologne, Medical care center for Gastroenterology, Berlin, RWTH Aachen University, University Hospital Erlangen, Zentrum für Klinische Studien Leipzig

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Systematic registry A primary outcome measure is not applicable as usual, since this data acquisition is performed to built a newly developed systematic registry which serves to describe - for the first time in Germany - the characteristics and the recent state of usual clinical care of the respective population.
Within the 18 months of recruitment and 3 years of individual follow-up for every patient regular analyses will be performed and published, based on a statistical analysis plan which may be yearly updated on request to address the main questions of the responsible PBC consortium.
After the end of data acquisition hepatologic scientists may apply with detailed proposals to further use available data. A scientific consortium will than decided on further analyses of data.
from baseline to 36 months after baseline (observational period)
Secondary Comprehensive clinical characterization of German PBC patients i.e. demographics, biochemical markers, ultrasound, transient elastography, stage of the disease from baseline to 36 months after baseline
Secondary Characterization of PBC therapies Characterization of UDCA as first line therapy and characterization of approved second-line treatment options such as OCALIVA.
Furthermore, safety data on the PBC medications used will be systematically gathered and reported on high-level aggregation with regard to any causality with PBC treatment per cohort. The respective results will be reviewed against the known safety profiles.
from baseline to 36 months after baseline
Secondary Treatment response to PBC therapies after 12 months and during longer courses of application To evaluate the natural progression under PBC drug therapy with respect to response to treatment changes in laboratory results (as ratios of the upper/lower limits of normal or differences to BL values) and characteristics of liver function will be described, e.g.:
frequency of hepatic decompensation (occurrence of variceal hemorrhage, ascites, encephalopathy, and/or hepatocellular carcinoma),
frequency of liver transplants,
frequency of deaths in total and from a liver-related cause, and
details on further events of special interest, e.g. for the first time serum bilirubin > ULN and/or alkaline phosphatase > 1.5 ULN, or transient elastography > 9.6 kPa.
from baseline to 12 months after baseline and to 36 months after baseline
Secondary Application and analyses of existing prognostic PBC scores to provide information on patients' prognosis. Details on typical therapeutic measures in treating PBC and patient compliance will be presented. This allows making a statement on quality of PBC treatment in Germany. Effectiveness will be assessed per cohort and compared between physicians' practices and hospital outpatient departments, aggregating data over all participating sites of the respective structure of health care. This refers to GLOBE score and/or Paris II criteria, frequency of hepatic decompensation or frequency of abnormal surrogate parameter (i.e. alkaline phosphatase, bilirubin, ALAT, ASAT or transient elastography). The respective results will be discussed against the results provided from clinical trials to verify everyday suitability of the different PBC therapies. from baseline to 36 months after baseline
Secondary Concomitant Medications Assessment of selected concomitant medications (e.g. symptomatic treatment of pru-ritus) from baseline to 36 months after baseline
Secondary Concomitant Autoimmune Diseases Assessment of selected concomitant autoimmune diseases (e.g. overlap syndrome with autoimmune hepatitis) from baseline to 36 months after baseline
Secondary Concomitant Non-Autoimmune Diseases Assessment of selected concomitant non-autoimmune diseases (i.e. cardiovascular disease, non-alcoholic fatty liver disease, metabolic syndrome, chronic kidney diseases) from baseline to 36 months after baseline
See also
  Status Clinical Trial Phase
Completed NCT02516605 - A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients Phase 2
Recruiting NCT06051617 - Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis Phase 3
Recruiting NCT06060665 - IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Phase 3
Recruiting NCT05450887 - Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis Phase 3
Recruiting NCT05050136 - A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis Phase 2
Recruiting NCT05151809 - National Database on Primary Biliary Cholangitis
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT03545672 - Early Identification of Myocardial Impairment in PBC
Completed NCT06098027 - Study of [14C]CS0159 in China Healthy Subjects Phase 1
Active, not recruiting NCT04594694 - Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Phase 2
Completed NCT03602560 - ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Phase 3
Suspended NCT03684187 - Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis N/A
Recruiting NCT04617561 - Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II Phase 4
Terminated NCT03092765 - Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid Phase 2
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT05919433 - Detection Program for Patients With Primary Biliary Cholangitis Lost in the System
Completed NCT06309589 - The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis N/A
Withdrawn NCT05293938 - A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
Completed NCT05292872 - Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients